by The drug discovery services market is projected to grow from USD 14.11 billion in 2022 and is forecasted to reach USD 33.2 billion by 2030; it is expected to grow at a CAGR of 11.3% from 2021 to 2030.
The study provides an analysis of the period 2017-2030, wherein 2021 to 2030 is the forecast period and 2021 is considered as the base year.
The global drug discovery services market is primarily driven by the increased investments in the research & development activities by the pharmaceutical and biologics companies across the globe. The rising prevalence of various disease and growing geriatric population across the globe are the major contributors to the demand for the pharmaceutical drugs. As per the United Nations, the geriatric population across the globe is estimated to reach 2 billion by 2050.
The elderly people are more susceptible to chronic diseases and hence spend more on the life-saving drugs. The increased need for the development of new and innovative drugs for the treatment of various common and rare diseases is fueling the demand for the drug discovery services. The patents expiry and growing demand for the biopharmaceutical drugs in the emerging economies is expected to drive the growth of the global drug discovery services market during the forecast period.
Get a Free Sample Copy of this Report with Global Industry Analysis @ https://www.precedenceresearch.com/sample/1532
Table of Contents
Scope of the Drug Discovery Services Market
| Report Coverage | Details |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Segments Covered | Drug Type, Process, Type,Therapeutic Area, Region |
Drug Discovery Services Market Estimations Y-O-Y:
- Market Size Was Valued In 2021: US$ 12.68 Billion
- Market Size Is Projected to Grow By 2022: US$ 14.11 Billion
- Market Size Is Projected to Grow By 2023: US$ 15.7 Billion
- Market Size Is Projected to Grow By 2024: US$ 17.47 Billion
- Market Size Is Projected to Grow By 2025: US$ 19.44 Billion
- Market Size Is Projected to Grow By 2026: US$ 21.64 Billion
- Market Size Is Projected to Grow By 2027: US$ 24.08 Billion
- Market Size Is Projected to Grow By 2028: US$ 26.81 Billion
- Market Size Is Projected to Grow By 2029: US$ 29.85 Billion
- Market Size Is Projected to Grow By 2030: US$ 33.2 Billion
- Compound Annual Growth Rate (CAGR) from 2022 to 2030: 11.3 percent
Drug Discovery Services Market Report Highlights
- Based on the drug type, the small molecules segment dominated the market in 2020, owing to its increased demand among the patients. The small molecules can effectively treat the infected cells with low or no side-effects, which makes it a popular drug among the population.
- Based on the type, the medicinal chemistry segment dominated the market in 2020. This is attributable to the increased applications of the medicinal chemistry from pre-clinical trials to the candidate delivery. The rising investments by the pharmaceutical companies in the drug discovery services are boosting the growth of this segment.
- Based on the therapeutic area, the oncology segment dominated the market in 2020. This is attributed to the increased prevalence of cancer among the population. According to the International Agency for Research on Cancer, around 19.3 million new cancer cases and around 10 million cancer deaths were reported in 2020. The new cancer cases are expected to rise by 47% from 2020 to 2040, globally.
Drug Discovery Services Market Dynamics
Driver
Increasing R & D expenditure by the pharmaceutical companies
According to the International Federation of Pharmaceutical Manufacturers & Associations, the pharmaceutical industry spent around US$150 billion in the research & development activities. It is estimated that on an average, a pharmaceutical company spends around 17% of its revenues on the research & development. Therefore, the rapidly growing pharmaceutical industry and surging investments by them in the R&D is expected to drive the growth of the global drug discovery services market during the forecast period.
Restraint
High costs associated with the drug discovery
A huge cost is involved in the services of drug discovery, owing to the higher attrition rate of the candidates during the development phase. Moreover, the research related to rare diseases requires a specific candidates’ group for the clinical trials. Moreover, the success rate is very low and the number of drugs that receives approval is very low. This involves a huge cost.
Opportunity
Rapidly growing biologics industry
The biologics industry has produced several life-saving innovative drugs that can cure chronic diseases such as cancer, diabetes, and CVDs. The rising awareness regarding the biologics is boosting the demand for the biologics. The biopharmaceuticals alone accounts for 20% of the pharmaceutical industry and is rapidly growing, which offers immense growth opportunities to the market players.
Challenge
Higher attrition rate of the candidates
The most difficult task in the drug discovery services is the identification and retention of the candidates in the clinical trials phase. The higher attrition rate of the candidates is a major challenge for the market players.
Regional Snapshot
In 2020, North America dominated the glob al drug discover services market. The increased prevalence of various chronic diseases in US is a major factor that attracts the investments from the pharmaceutical companies towards the research and drug discovery activities. As peer the CDC, around 92.1 million adults in US are suffering from at least one type of cardiovascular disease. It is estimated that over half of the US population is suffering from at least one chronic disease such as cancer, CVDs, respiratory diseases, and neurological disorders.
This results in the increased demand for the new and innovative drugs. Moreover, as per the Population Reference Bureau, the number of people aged 65 years and above is expected to reach at 95 million in US by 2060. The geriatric people has higher demand for the various life-saving drugs as they are more prone to various diseases. The presence of several top pharmaceutical companies in the region results in the increased investments towards the drug discovery activities.
Asia Pacific is estimated to be the most opportunistic market during the forecast period. The rising investments by the top global players in the region owing to the cheap availability of factors of production, availability of several top research companies, and favorable government regulations are collectively driving the growth of the drug discovery services market. The rising geriatric population and rising prevalence of chronic diseases due to various reasons is supplementing the demand for the innovative life-saving drugs, which fuels the investments towards the drug discovery services.
Read Also: Ear Nose Throat (ENT) Treatment Market to Reach US$ 27.95 billion by 2030
Some of the prominent players in the global drug discovery services market include:
- Abbott Laboratories Inc.
- Advinus Therapeutics
- Agilent Technologies Ubiquigent
- Albany Molecular Research Inc.
- AstraZeneca PLC
- Aurigene
- Bayer AG
- Charles River Laboratories International
- ChemBridge Corporation
- Covance
Market Segmentation
By Process
- Target Selection
- Target Validation
- Hit to Lead Identification
- Lead Optimization
- Candidate Validation
By Drug Type
- Small Molecules
- Biologics
By Type
- DMPK
- Biology Services
- Medicinal Chemistry
By Therapeutic Area
- Oncology
- Cardiovascular Diseases
- Diabetes
- Neurology
- Respiratory Diseases
- Others
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Drug Discovery Services Market
5.1. COVID-19 Landscape: Drug Discovery Services Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Drug Discovery Services Market, By Process
8.1. Drug Discovery Services Market, by Process Type, 2021-2030
8.1.1. Target Selection
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Target Validation
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Hit to Lead Identification
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Lead Optimization
8.1.4.1. Market Revenue and Forecast (2019-2030)
8.1.5. Candidate Validation
8.1.5.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Drug Discovery Services Market, By Drug Type
9.1. Drug Discovery Services Market, by Drug Type, 2021-2030
9.1.1. Small Molecules
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Biologics
9.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Drug Discovery Services Market, By Type
10.1. Drug Discovery Services Market, by Type, 2021-2030
10.1.1. DMPK
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Biology Services
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. Medicinal Chemistry
10.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Drug Discovery Services Market, By Therapeutic Area
11.1. Drug Discovery Services Market, by Therapeutic Area Type, 2021-2030
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast (2019-2030)
11.1.2. Cardiovascular Diseases
11.1.2.1. Market Revenue and Forecast (2019-2030)
11.1.3. Diabetes
11.1.3.1. Market Revenue and Forecast (2019-2030)
11.1.4. Neurology
11.1.4.1. Market Revenue and Forecast (2019-2030)
11.1.5. Respiratory Diseases
11.1.5.1. Market Revenue and Forecast (2019-2030)
11.1.6. Others
11.1.6.1. Market Revenue and Forecast (2019-2030)
Chapter 12. Global Drug Discovery Services Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Process (2019-2030)
12.1.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.1.3. Market Revenue and Forecast, by Type (2019-2030)
12.1.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Process (2019-2030)
12.1.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.1.5.3. Market Revenue and Forecast, by Type (2019-2030)
12.1.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Process (2019-2030)
12.1.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.1.6.3. Market Revenue and Forecast, by Type (2019-2030)
12.1.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Process (2019-2030)
12.2.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.2.3. Market Revenue and Forecast, by Type (2019-2030)
12.2.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Process (2019-2030)
12.2.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.2.5.3. Market Revenue and Forecast, by Type (2019-2030)
12.2.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Process (2019-2030)
12.2.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.2.6.3. Market Revenue and Forecast, by Type (2019-2030)
12.2.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Process (2019-2030)
12.2.7.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.2.7.3. Market Revenue and Forecast, by Type (2019-2030)
12.2.7.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Process (2019-2030)
12.2.8.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.2.8.3. Market Revenue and Forecast, by Type (2019-2030)
12.2.8.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Process (2019-2030)
12.3.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.3.3. Market Revenue and Forecast, by Type (2019-2030)
12.3.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Process (2019-2030)
12.3.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.3.5.3. Market Revenue and Forecast, by Type (2019-2030)
12.3.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Process (2019-2030)
12.3.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.3.6.3. Market Revenue and Forecast, by Type (2019-2030)
12.3.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Process (2019-2030)
12.3.7.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.3.7.3. Market Revenue and Forecast, by Type (2019-2030)
12.3.7.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Process (2019-2030)
12.3.8.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.3.8.3. Market Revenue and Forecast, by Type (2019-2030)
12.3.8.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Process (2019-2030)
12.4.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.4.3. Market Revenue and Forecast, by Type (2019-2030)
12.4.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Process (2019-2030)
12.4.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.4.5.3. Market Revenue and Forecast, by Type (2019-2030)
12.4.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Process (2019-2030)
12.4.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.4.6.3. Market Revenue and Forecast, by Type (2019-2030)
12.4.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Process (2019-2030)
12.4.7.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.4.7.3. Market Revenue and Forecast, by Type (2019-2030)
12.4.7.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Process (2019-2030)
12.4.8.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.4.8.3. Market Revenue and Forecast, by Type (2019-2030)
12.4.8.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Process (2019-2030)
12.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.5.3. Market Revenue and Forecast, by Type (2019-2030)
12.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Process (2019-2030)
12.5.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.5.5.3. Market Revenue and Forecast, by Type (2019-2030)
12.5.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Process (2019-2030)
12.5.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.5.6.3. Market Revenue and Forecast, by Type (2019-2030)
12.5.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)
Chapter 13. Company Profiles
13.1. Abbott Laboratories Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Advinus Therapeutics
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Agilent Technologies Ubiquigent
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Albany Molecular Research Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. AstraZeneca PLC
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Aurigene
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Bayer AG
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Charles River Laboratories International
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. ChemBridge Corporation
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Covance
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Why should you invest in this report?
If you are aiming to enter the global drug discovery services market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for drug discovery services are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1532
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
